Early Warning Wearable Device (EWWD) Project. An innovative remote monitoring solution that supports patients with Musculoskeletal Disorders and diabetes, whilst creating efficiencies in clinical management of disorders. (Q4294366): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Attach the beneficiary based on the string) |
(Changed an Item: Attach the beneficiary based on the string) |
||
| Property / beneficiary | |||
Q4384567 (Deleted Item) | |||
| Property / beneficiary: Q4384567 (Deleted Item) / rank | |||
Normal rank | |||
Revision as of 12:23, 22 June 2022
Project Q4294366 in Switzerland, France, United Kingdom
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Early Warning Wearable Device (EWWD) Project. An innovative remote monitoring solution that supports patients with Musculoskeletal Disorders and diabetes, whilst creating efficiencies in clinical management of disorders. |
Project Q4294366 in Switzerland, France, United Kingdom |
Statements
7,349,850.54 Euro
0 references
10,731,508.87 Euro
0 references
68.49 percent
0 references
24 July 2020
0 references
30 December 2022
0 references
Hextransforma Healthcare Limited
0 references
Q4384567 (Deleted Item)
0 references
49°11'14.68"N, 0°18'34.27"W
0 references
50°45'18.79"N, 0°16'12.68"E
0 references
50°45'18.83"N, 0°16'12.47"E
0 references
50°49'32.27"N, 0°8'29.65"W
0 references
47°17'8.52"N, 8°37'24.42"E
0 references
49°26'25.51"N, 1°5'33.90"E
0 references
50°50'9.53"N, 0°10'18.70"W
0 references
48°5'10.00"N, 1°40'25.25"W
0 references
51°20'28.43"N, 0°15'59.04"W
0 references
51°29'6.11"N, 3°9'55.91"W
0 references
The Early Warning Wearable Device (EWWD) project will deliver a suite (wrist-worn; body-worn in-soles) of wearable devices linked to an Artificial Intelligence (AI) driven software service that remotely monitors patients (pre & post operative) suffering from Musculoskeletal Disorders (MSDs) and Types I & II Diabetes (Neuropathy & Charcot foot). The project will enable the take up of 10 new tech products (hardware & softtware), new treatment processes, patient monitoring systems & treatment pathway services in shared smart specialisation sectors. The devices will be taken from Technology Readiness levels (TRL) 3-9 culminating in observational trials. Remote monitoring and early intervention will save the UK & French health systems & broader economy €71,650 per patient p.a. & significantly improve patient outcomes. Pre-Op remote monitoring automatically reviews patient status based on reported real-time data & identifies improvement or deterioration of the patient’s condition & builds a baseline data-set that will be comparable to post-op data. Monitoring of Diabetes sufferers gives an early indication of deterioration (neuropathy) & allows for early intervention, reducing the number of clinical appointments as well as the risk of developing more severe conditions resulting in amputation. 30% of MSK patients undergoing surgery experience post-op complications & infections, resulting in additional costs of readmission, frequently through ICU, at significantly higher costs (€400 per day compared to €28 for an outpatient consultation). The innovation will allow more patients to be treated in an outpatient environment. Deployment in the FCE area, in a cross-border approach, allows for a broad and rigorous observational trial, bringing togther experts to improve the solution. The Partnership allows for the proliferation of ideas and adapts design to ensure solutions can be deployed in multiple EU states. Outputs will be: 10 new products (wrist/body/shoe worn devices); Software as a Service (SaaS) clinical desktop; Patient analytics desktop service; AI Platfrom; Improved patient outcomes data; data-lake. 9 businesses will cooperate with 4 research institutions [Cardiff Uni.; Uni. of Sussex, Rennes2 Uni., Caen-Normany Uni] participating in a cross-border interregional research project. The project delivers savings by reducing the number of diagnosis appointments; creates an objective patient prioritisation process; a scalable solution for MSD management; Improves clinician effectiveness & efficiency; Reduces treatment cost. The Innovation will reduce the number & cost of post-op emergency admissions through the early identification & treatment of complications & infections. The project will also deliver employment aspiration and social mobility across the FCE area through a Med-Tech competition involving more than 40 UK schools and impacting 50,000 students as well as the employment & training of 6 young people from socially deprived backgrounds. (English)
0 references